TCGA-O1-A52J-01A-11R-A262-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.340
- INTERFERON_ALPHA_RESPONSE+0.260
- XENOBIOTIC_METABOLISM+0.240
- IL6_JAK_STAT3_SIGNALING+0.230
- KRAS_SIGNALING_DN+0.170
- COAGULATION+0.150
- FATTY_ACID_METABOLISM+0.150
- INTERFERON_GAMMA_RESPONSE+0.150
- INFLAMMATORY_RESPONSE+0.130
- MYOGENESIS+0.130
Top 10 suppressed
- E2F_TARGETS-0.580
- MYC_TARGETS_V1-0.580
- G2M_CHECKPOINT-0.540
- MYC_TARGETS_V2-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.420
- WNT_BETA_CATENIN_SIGNALING-0.370
- TGF_BETA_SIGNALING-0.330
- DNA_REPAIR-0.320
- MTORC1_SIGNALING-0.320
- ANGIOGENESIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598293 | fetal | fetal | 0.900 |
| 2 | TCGA-MP-A4SW-01A-21R-A24X-07 | — | cohortA1 | 0.886 |
| 3 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.870 |
| 4 | TCGA-62-A46Y-01A-11R-A24H-07 | — | cohortA1 | 0.868 |
| 5 | TCGA-67-6217-01A-11R-1755-07 | — | cohortA1 | 0.860 |
| 6 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.857 |
| 7 | TCGA-97-A4M6-01A-11R-A24X-07 | — | cohortA1 | 0.844 |
| 8 | SRR657151 | GTEX | — | 0.841 |
| 9 | BS_2SFTWNVE | Med | Medulloblastoma | 0.840 |
| 10 | TCGA-44-2657-01A-01R-1107-07 | — | cohortA1 | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| APOPTOSIS | 0.070 | Idelalisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.050 | Idelalisib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |